SAN DIEGO, Calif. and CAMBRIDGE, UK - Jan 18, 2022 - CS Genetics, a privately held genomics-technology company, today announced the appointment of Jeremy Preston, PhD, as Chief Commercial Officer. Jeremy will lead global sales, marketing, and customer-support activities as the company launches its single cell genomics technology, which employs a simple, single-day cells-to-sequencer workflow and leverages instrument-free, solution-phase chemical biology that plugs directly into existing laboratory infrastructure.
Jeremy joins CS Genetics from Illumina where he held a variety of senior leadership roles across sales, marketing, and product management, most recently serving as Vice President of Regional and Segment Marketing where he led a global team of ~200 across the Americas, EMEA, Asia-Pacific and Japan, and Greater China. His earlier roles at Illumina include Vice President of Specialty Sales and Marketing, as well as Senior Director of Product Marketing, during which time Jeremy led product management for the complete series of HiSeq sequencers, NextSeq 500/550, MiSeq/MiSeqDx, foundational stages of the NovaSeq, MiniSeq, and iSeq programs, and other systems/consumables and library prep families, which collectively account for over $2B in annual sales. Prior to Illumina, Jeremy was Associate Director of Product Marketing at Affymetrix, where he managed the firm's gene expression portfolio. Jeremy completed his postdoctoral research in Molecular Biology at RIKEN in Yokohama, Japan, and his PhD in Molecular Biology at La Trobe University in Melbourne, Australia.
“It’s an incredible privilege to partner with Jeremy to launch and drive commercial adoption of our new single cell genomics platform” said Luke Edelman, PhD, Chief Executive Officer at CS Genetics. “Jeremy is one of the most experienced and strategic commercial operators in genomics and has played a major role in commercializing some of the most rapidly-adopted and widely-used products in life science. He’s also an exceptionally collaborative, team-based leader who naturally inspires a positive, supportive culture, and has a clear personal belief in the power of genomic technology to accelerate scientific discovery and advance patient care. We’re thrilled to welcome him aboard.”
CS Genetics has developed a disruptive platform for single cell genomics which leverages instrument-free, solution-phase chemical biology instead of solid-phase hardware or complex, multi-step/multi-tube indexing schemes. CS Genetics’ platform offers a simple, single-day cells-to-sequencer workflow that requires only standard laboratory plasticware, the ability to rapidly deploy on existing high-throughput lab-automation infrastructure, a unique fixation-free workflow pause-point at cell collection to enable asynchronous sample collection/storage, and a cost profile that is structurally inaccessible to leading on-market single-cell platforms.
“The single cell market has grown explosively in the past 5 years as scientists seek to understand biology at the cellular level. CS Genetics’ technology is poised for widespread, high-impact uptake because it offers labs a simple and elegant solution that is affordable, easily adoptable and scalable, allowing access to more samples for basic, translational, and clinical research. I’m enormously excited to partner with Luke and the talented CS Genetics team to deliver their products to researchers around the world,” said Jeremy Preston, Chief Commercial Officer at CS Genetics.
About CS Genetics
CS Genetics is a privately held genomics-technology company based in San Diego, California and Cambridge, UK. The company's product portfolio leverages instrument-free, solution-phase chemical biology that is categorically different to other single cell technologies, providing a clear commercial path globally without the extensive, multi-prong litigation risks borne by other platforms within the single cell market. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, please contact info@csgenetics.com.
SAN DIEGO, Calif. and CAMBRIDGE, UK - Mar 15, 2022 - CS Genetics, a privately held genomics-technology company, today announced the appointment of Jay Harger, PhD, as Senior Vice President of Operations. Jay will lead a variety of critical company operations including facilities, manufacturing and supply chain, and portfolio management as the company launches its single cell genomics technology, which employs a simple, single-day cells-to-sequencer workflow and leverages instrument-free, solution-phase chemical biology that plugs directly into existing laboratory infrastructure.
Jay joins CS Genetics from Illumina where he held a variety of senior leadership roles across operations, product and portfolio management, product support, and clinical infrastructure, most recently serving as Senior Director of Product Management where he oversaw Illumina's core Library Prep strategy. His earlier roles at Illumina include Senior Director of Portfolio Management, where he led program management and R&D support for Illumina's entire $3.5B on-market product portfolio, as well as Senior Director of Clinical Genomics Product Lifecycle Management, Director of Clinical Transformation, and Associate Director of Supply Chain Programs. Jay completed his postdoctoral research in Chemical Biology at The Scripps Research Institute, and his PhD in Molecular Genetics at Rutgers.
“We're thrilled to partner with Jay to deliver our new single cell genomics platform to the global research community” said Luke Edelman, PhD, Chief Executive Officer at CS Genetics. “Jay has an incredibly impressive track record of delivering scalable systems and strategies in genomics, from product and portfolio strategy, to manufacturing and supply chain. His expertise spans diverse product domains in both research and clinical-diagnostic markets, and he brings a highly inclusive leadership style to building and inspiring high-performing teams. Jay is an incredible addition to our team as we execute our ambitious product roadmap across this year and beyond."
CS Genetics has developed a disruptive platform for single cell genomics which leverages instrument-free, solution-phase chemical biology instead of solid-phase hardware or complex, multi-step/multi-tube indexing schemes. CS Genetics’ platform offers a simple, single-day cells-to-sequencer workflow that requires only standard laboratory plasticware, the ability to rapidly deploy on existing high-throughput lab-automation infrastructure, a unique fixation-free workflow pause-point at cell collection to enable asynchronous sample collection/storage, and a cost profile that is structurally inaccessible to leading on-market single-cell platforms.
"As costs for sequencing come down, the opportunities for high-value upstream workflow technologies such as single cell genomics become larger. Single cell is a holy grail of high-resolution biological measurement, but the complexity and cost of current technologies severely constrain their adoption and impact across fundamental research, biopharma, and beyond. The elegance and simplicity of the CS Genetics platform make it impressively positioned to address major technical and practical challenges in single cell, which is why I am so excited to join Luke and the CS Genetics team to operationalize and scale this technology very widely in the years ahead.” said Jay Harger, Senior Vice President of Operations at CS Genetics.
About CS Genetics
CS Genetics is a privately held genomics-technology company based in San Diego, California and Cambridge, UK. The company's product portfolio leverages instrument-free, solution-phase chemical biology that is categorically different to other single cell technologies, providing a clear commercial path globally without the extensive, multi-prong litigation risks borne by other platforms within the single cell market. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, please contact info@csgenetics.com.
SAN DIEGO, Calif. and CAMBRIDGE, UK - Apr 19, 2022 - CS Genetics, a privately held genomics-technology company, today announced the appointment of Chad Geringer as Vice President of Global Sales. Chad will build and lead the company's global sales organization as the company launches its single cell genomics technology, which employs a simple, single-day cells-to-sequencer workflow and leverages instrument-free, solution-phase chemical biology that plugs directly into existing laboratory infrastructure.
Chad joins CS Genetics from Twist Bioscience where he served as Director of Americas and EMEA sales for their NGS product portfolio. Prior to Twist, Chad spent over 15 years at Illumina where he held a variety of sales, support, and broader commercial roles across the world, including Director of Global Commercial Partnerships, and Head of Regional Accounts and Technologies in EMEA. Chad also spent nearly a decade as a laboratory scientist at Eli Lilly, where he applied genomics technologies to projects spanning drug discovery and development. Chad completed his Master's in Medical and Molecular Genetics at Indiana University.
“We're excited to partner with Chad to deliver our disruptive products for single cell genomics to customers around the world” said Jeremy Preston, PhD, Chief Commercial Officer at CS Genetics. “Chad brings a wealth of leadership and commercial experience in genomics spanning diverse products, geographies and markets. He also brings deep technical knowledge, intimate understanding of applications and needs across key customer types, and a passion for enabling scientists with ground-breaking technology. It's a privilege to welcome a recognized industry leader of Chad’s caliber to spearhead our high-performance global sales organization"
CS Genetics has developed a disruptive platform for single cell genomics which leverages instrument-free, solution-phase chemical biology instead of solid-phase hardware or complex, multi-step/multi-tube indexing schemes. CS Genetics’ platform offers a simple, single-day cells-to-sequencer workflow that requires only standard laboratory plasticware, the ability to rapidly deploy on existing high-throughput lab-automation infrastructure, a unique fixation-free workflow pause-point at cell collection to enable asynchronous sample collection/storage, and a cost profile that is structurally inaccessible to leading on-market single-cell platforms.
“I’m thrilled by the opportunity to serve the scientific community with CS Genetics’ highly enabling single cell technology. Over the course of my career I have been involved with several other disruptive genomics technologies and immediately recognized the potential for CS Genetics’ single cell solution to unlock new markets and truly democratize single cell genomics. The simplicity and scalability of the technology will enable scientists across the spectrum to adopt single cell – from small, academic research labs to large biopharma.” said Chad Geringer, Vice President of Global Sales at CS Genetics.
About CS Genetics
CS Genetics is a privately held genomics-technology company based in San Diego, California and Cambridge, UK. The company's product portfolio leverages instrument-free, solution-phase chemical biology that is categorically different to other single cell technologies, providing a clear commercial path globally without the extensive, multi-prong litigation risks borne by other platforms within the single cell market. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, please contact info@csgenetics.com.